AIMS/HYPOTHESIS: The insulin-dependent diabetes mellitus 2 gene (IDDM2) is a type 1 diabetes susceptibility locus contributed to by the variable number of tandem repeats (VNTR) upstream of the insulin gene (INS). We investigated the association between INS VNTR class III alleles (-23HphIA/T) and both insulin antibody presentation and residual beta cell function during the first year after diagnosis in 257 children with type 1 diabetes. MATERIALS AND METHODS: To estimate C-peptide levels and autoantibody presentation, patients underwent a meal-stimulated C-peptide test 1, 6, and 12 months after diagnosis. The insulin -23HphIA/T variant was used as a marker of class III alleles and genotyped by PCR-RFLP. RESULTS: The insulin antibody titres at 1 and 6 months were significantly lower in the class III/III and class I/III genotype groups than in the class I/I genotype group (p = 0.01). Class III alleles were also associated with residual beta cell function 12 months after diagnosis and independently of age, sex, BMI, insulin antibody titres, and HLA-risk genotype group (p = 0.03). The C-peptide level was twice as high among class III/III genotypes as in class I/I and class I/III genotypes (319 vs 131 and 166 pmol/l, p=0.01). Furthermore, the class III/III genotype had a 1.1% reduction in HbA(1)c after adjustment for insulin dose (p = 0.04). CONCLUSIONS/ INTERPRETATION: These findings suggest a direct connection in vivo between INS VNTR class III alleles, a decreased humoral immune response to insulin, and preservation of beta cell function in recent-onset type 1 diabetes.
AIMS/HYPOTHESIS: The insulin-dependent diabetes mellitus 2 gene (IDDM2) is a type 1 diabetes susceptibility locus contributed to by the variable number of tandem repeats (VNTR) upstream of the insulin gene (INS). We investigated the association between INS VNTR class III alleles (-23HphIA/T) and both insulin antibody presentation and residual beta cell function during the first year after diagnosis in 257 children with type 1 diabetes. MATERIALS AND METHODS: To estimate C-peptide levels and autoantibody presentation, patients underwent a meal-stimulated C-peptide test 1, 6, and 12 months after diagnosis. The insulin -23HphIA/T variant was used as a marker of class III alleles and genotyped by PCR-RFLP. RESULTS: The insulin antibody titres at 1 and 6 months were significantly lower in the class III/III and class I/III genotype groups than in the class I/I genotype group (p = 0.01). Class III alleles were also associated with residual beta cell function 12 months after diagnosis and independently of age, sex, BMI, insulin antibody titres, and HLA-risk genotype group (p = 0.03). The C-peptide level was twice as high among class III/III genotypes as in class I/I and class I/III genotypes (319 vs 131 and 166 pmol/l, p=0.01). Furthermore, the class III/III genotype had a 1.1% reduction in HbA(1)c after adjustment for insulin dose (p = 0.04). CONCLUSIONS/ INTERPRETATION: These findings suggest a direct connection in vivo between INS VNTR class III alleles, a decreased humoral immune response to insulin, and preservation of beta cell function in recent-onset type 1 diabetes.
Authors: Hironori Ueda; Joanna M M Howson; Laura Esposito; Joanne Heward; Hywel Snook; Giselle Chamberlain; Daniel B Rainbow; Kara M D Hunter; Annabel N Smith; Gianfranco Di Genova; Mathias H Herr; Ingrid Dahlman; Felicity Payne; Deborah Smyth; Christopher Lowe; Rebecca C J Twells; Sarah Howlett; Barry Healy; Sarah Nutland; Helen E Rance; Vin Everett; Luc J Smink; Alex C Lam; Heather J Cordell; Neil M Walker; Cristina Bordin; John Hulme; Costantino Motzo; Francesco Cucca; J Fred Hess; Michael L Metzker; Jane Rogers; Simon Gregory; Amit Allahabadia; Ratnasingam Nithiyananthan; Eva Tuomilehto-Wolf; Jaakko Tuomilehto; Polly Bingley; Kathleen M Gillespie; Dag E Undlien; Kjersti S Rønningen; Cristian Guja; Constantin Ionescu-Tîrgovişte; David A Savage; A Peter Maxwell; Dennis J Carson; Chris C Patterson; Jayne A Franklyn; David G Clayton; Laurence B Peterson; Linda S Wicker; John A Todd; Stephen C L Gough Journal: Nature Date: 2003-04-30 Impact factor: 49.962
Authors: S J Huxtable; P J Saker; L Haddad; M Walker; T M Frayling; J C Levy; G A Hitman; S O'Rahilly; A T Hattersley; M I McCarthy Journal: Diabetes Date: 2000-01 Impact factor: 9.461
Authors: J Nerup; P Platz; O O Andersen; M Christy; J Lyngsoe; J E Poulsen; L P Ryder; L S Nielsen; M Thomsen; A Svejgaard Journal: Lancet Date: 1974-10-12 Impact factor: 79.321
Authors: P Vafiadis; S T Bennett; J A Todd; J Nadeau; R Grabs; C G Goodyer; S Wickramasinghe; E Colle; C Polychronakos Journal: Nat Genet Date: 1997-03 Impact factor: 38.330
Authors: Robert Hermann; A P Laine; R Veijola; T Vahlberg; S Simell; J Lähde; O Simell; M Knip; J Ilonen Journal: Diabetologia Date: 2005-07-16 Impact factor: 10.122
Authors: Jinko Graham; William A Hagopian; Ingrid Kockum; Lou Sheng Li; Carani B Sanjeevi; Robert M Lowe; Jonathan B Schaefer; Marjan Zarghami; Heather L Day; Mona Landin-Olsson; Jerry P Palmer; Marta Janer-Villanueva; Leroy Hood; Göran Sundkvist; Ake Lernmark; Norman Breslow; Gisela Dahlquist; Göran Blohmé Journal: Diabetes Date: 2002-05 Impact factor: 9.461
Authors: Robert Hermann; A P Laine; R Veijola; T Vahlberg; S Simell; J Lähde; O Simell; M Knip; J Ilonen Journal: Diabetologia Date: 2005-07-16 Impact factor: 10.122
Authors: Sven Pörksen; Lene Bjerke Laborie; Lotte Nielsen; Marie Louise Max Andersen; Tone Sandal; Heidi de Wet; Erik Schwarcz; Jan Aman; Peter Swift; Mirjana Kocova; Eugen J Schönle; Carine de Beaufort; Philip Hougaard; Frances Ashcroft; Anders Molven; Mikael Knip; Henrik B Mortensen; Lars Hansen; Pål R Njølstad Journal: BMC Endocr Disord Date: 2010-09-23 Impact factor: 2.763
Authors: Lotte B Nielsen; Sven Pörksen; Marie Louise M Andersen; Siri Fredheim; Jannet Svensson; Philip Hougaard; Maurizio Vanelli; Jan Åman; Henrik B Mortensen; Lars Hansen Journal: BMC Med Genet Date: 2011-03-23 Impact factor: 2.103
Authors: Caroline A Brorsson; Lotte B Nielsen; Marie Louise Andersen; Simranjeet Kaur; Regine Bergholdt; Lars Hansen; Henrik B Mortensen; Flemming Pociot; Joachim Størling Journal: J Diabetes Res Date: 2016-01-20 Impact factor: 4.011
Authors: Marie Louise Max Andersen; Morten Arendt Rasmussen; Sven Pörksen; Jannet Svensson; Jennifer Vikre-Jørgensen; Jane Thomsen; Niels Thomas Hertel; Jesper Johannesen; Flemming Pociot; Jacob Sten Petersen; Lars Hansen; Henrik Bindesbøl Mortensen; Lotte Brøndum Nielsen Journal: PLoS One Date: 2013-06-05 Impact factor: 3.240